Skip to main content
NewslettersWatchlist

Trevena Inc(TRVN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Trevena Reports Second Quarter 2022 Results and Provides Business Update

Globe Newswire - Thu Aug 11, 2022

OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study

Phase 1 study for TRV045, a novel S1P receptor modulator, on track for year-end data readout; single ascending dose and food effect study segments fully enrolled

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Dividend investing has lost its mojo. Here’s why – and how to adapt
Ian McGugan
inside the market
The Globe Investing Club 2024: Let the competition begin!
opinion
Here’s the real reason your Canadian stocks can’t keep up
Tim Shufelt
market news
Dow ends above 40,000 milestone, TSX also at fresh record high
Traders work on the floor of the New York Stock Exchange (NYSE) on May 16.
number cruncher
U.S technology stocks with earnings and price momentum
For Number Cruncher column in Globe Investor/ROB only.
report on business
Lightspeed Commerce stock soars on better-than-expected profit forecast
Lightspeed Commerce Inc. CEO Dax Dasilva poses in the company's offices in Montreal, Wednesday, May 8, 2024. THE CANADIAN PRESS/Christinne Muschi
globe investor
GameStop, AMC dive further as meme stocks rally tapers off
A screen displays the trading information for GameStop and AMC Theatres on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 15.
market news
The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).